scholarly journals POS-027 Critical illness and systemic inflammation are key risk factors of severe AKI in patients with COVID-19

2021 ◽  
Vol 6 (4) ◽  
pp. S12
Author(s):  
J.H.B. HARDENBERG ◽  
H. Stockmann ◽  
A. Aigner ◽  
K.U. Eckardt ◽  
K. Schmidt-Ott
Author(s):  
Jan-Hendrik B. Hardenberg ◽  
Helena Stockmann ◽  
Annette Aigner ◽  
Inka Gotthardt ◽  
Philipp Enghard ◽  
...  

2016 ◽  
Vol 56 (3) ◽  
pp. 129
Author(s):  
Nadya Arafuri ◽  
Pudjo Hagung Widjajanto ◽  
Ekawaty L. Haksari

Background Albumin transfusion for the treatment of neonatal hypoalbuminemia may reduce morbidity. In conditions with disrupted endothelial integrity (e.g., sepsis and critical illness), the administered albumin may leak into the interstitial space, hence, serum albumin levels may fall below expected levels after transfusion. To date, few studies have been done to evaluate the risk factors for failure to achieve normal neonatal albumin levels after transfusion.Objectives To determine the risk factors for failure to achieve normal neonatal albumin levels after transfusion.Methods We performed a case-control study in the Neonatal Ward of Dr. Sardjito Hospital from 2007 to 2012. Normal albumin level was defined as above 3 g/dL. The case group included neonates with post-transfusion albumin levels <3 g/dL and the control group included those with post-transfusion albumin ≥3 g/dL. Subjects received intravenous transfusions of 25% or 20% albumin according to the clinical standard of the Neonatal Ward of Dr. Sardjito Hospital. Neonates with very low birth weight, severe birth trauma, burn injuries, severe bleeding, or incomplete medical records were excluded. The data were analyzed with logistic regression test.Results From January 2007 to December 2012, 124 neonates were enrolled in the study. Multivariate analysis showed that low albumin levels before transfusion (OR 12.27; 95%CI 2.17 to 69.30), presence of critical illness (OR 4.01; 95%CI 1.49 to 10.79), diagnosis of sepsis (OR 3.56; 95%CI 1.36 to 9.32), and the >24-hour interval between albumin examination and transfusion (OR 0.06; 95%CI 0.01 to 0.37) were significant risk factors affecting the failure to achieve normal albumin levels.Conclusions Failure to achieve normal albumin levels after transfusion in neonates was significantly associated with low albumin level prior to transfusion, critical illness, sepsis, and >24-hour interval between transfusion and post-transfusion albumin examination.[Paediatr Indones. 2016;56:129-33.].


2017 ◽  
Vol 42 ◽  
pp. 405-406
Author(s):  
Paola Tonin Carpeggiani ◽  
Júlia Bertholdo Bossardi ◽  
Fabricio Piccoli Fortuna ◽  
Vanessa Piccoli ◽  
Nicole Elen Lira ◽  
...  

2018 ◽  
Vol 46 (6) ◽  
pp. e530-e539 ◽  
Author(s):  
Nita Khandelwal ◽  
Catherine L. Hough ◽  
Lois Downey ◽  
Ruth A. Engelberg ◽  
Shannon S. Carson ◽  
...  

2019 ◽  
Vol 50 ◽  
pp. 31-35
Author(s):  
C.E. Battle ◽  
C. Lynch ◽  
C. Thorpe ◽  
S. Biggs ◽  
K. Grobbelaar ◽  
...  

Author(s):  
Elisabetta Schiaroli ◽  
Anna Gidari ◽  
Giovanni Brachelente ◽  
Sabrina Bastianelli ◽  
Alfredo Villa ◽  
...  

IntroductionCOVID-19 is characterized by a wide range of clinical expression and by possible progression to critical illness and death. Therefore it is essential to identify risk factors predicting progression towards serious and fatal diseases. The aim of our study was to identify laboratory predictive markers of clinical progression in patients with moderate/severe disease and in those with acute respiratory distress syndrome (ARDS).Material and methodsUsing electronic medical records for all demographic, clinical and laboratory data, a retrospective study on all consecutive patients with COVID-19 admitted to the Infectious Disease Clinic of Perugia was performed. The PaO2/FiO2 ratio (P/F) assessment cut‑off of 200 mm Hg was used at baseline to categorize the patients into two clinical groups. The progression towards invasive ventilation and/or death was used to identify critical outcome. Statistical analysis was performed. Multivariate logistic regression analysis was adopted to identify risk factors of critical illness and mortality.ResultsIn multivariate logistic regression analysis neutrophil/lymphocyte ratio (NLR) was the only significant predictive factor of progression to a critical outcome (p = 0.03) and of in-hospital mortality (p = 0.03). In ARDS patients no factors were associated with critical progression. Serum ferritin > 1006 ng/ml was the only predictive value of critical outcome in COVID-19 subjects with moderate/severe disease (p = 0.02).ConclusionsNeutrophil/lymphocyte ratio and serum ferritin are the only biomarkers that can help to stratify the risk of severity and mortality in patients with COVID-19.


2021 ◽  
pp. 101-121
Author(s):  
O. Joseph Bienvenu ◽  
Megan M Hosey

Patients with critical illnesses face a number of severe psychic and physical stressors. Survivors often have long-term cognitive and physical impairments, as well as family, financial, and other stressors. These potential stressors increase the risk of psychiatric disturbances substantially. This chapter describes the burden of distress-related psychiatric morbidity in patients who survive critical illnesses, as well as risk factors for this morbidity. This knowledge serves as the motivation to develop new approaches that can ameliorate, or even prevent, long-term distress in survivors. The chapter also presents information about early attempts to reduce, prevent, and manage long-term psychological morbidity.


Author(s):  
Max L. Gunther ◽  
James C. Jackson ◽  
Pratik Pandharipande ◽  
Alessandro Morandi ◽  
Maureen Hahn ◽  
...  

Author(s):  
Mark W Hall ◽  
Ila Joshi ◽  
Luis Leal ◽  
Eng Eong Ooi

Abstract We are learning that the host response to severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2) infection is complex and highly dynamic. Effective initial host defense in the lung is associated with mild symptoms and disease resolution. Viral evasion of the immune response can lead to refractory alveolar damage, ineffective lung repair mechanisms, and systemic inflammation with associated organ dysfunction. The immune response in these patients is highly variable and can include moderate to severe systemic inflammation and/or marked systemic immune suppression. There is unlikely to be a “one size fits all” approach to immunomodulation in patients with coronavirus disease 2019 (COVID-19). We believe that a personalized, immunophenotype-driven approach to immunomodulation that may include anticytokine therapy in carefully selected patients and immunostimulatory therapies in others is the shortest path to success in the study and treatment of patients with critical illness due to COVID-19.


2018 ◽  
Vol 19 (3) ◽  
pp. e164-e171 ◽  
Author(s):  
Alicia G. Kachmar ◽  
Sharon Y. Irving ◽  
Cynthia A. Connolly ◽  
Martha A. Q. Curley

Sign in / Sign up

Export Citation Format

Share Document